Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates

Journal of Clinical Oncology

Volumn 27, Issue 10, 2009, Pages 1564-1571

  Fizazi, Karim ^a   Lipton, Allan ^a   Mariette, Xavier ^a   Body, Jean Jacques ^a   Rahim, Yasmin ^a   Gralow, Julie R ^a   Gao, Guozhi ^a   Wu, Ling ^a   Sohn, Winnie ^a   Jun, Susie ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; CALCIUM; COLLAGEN; CREATININE; DENOSUMAB; DRUG ANTIBODY; IBANDRONIC ACID; PAMIDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BACKACHE; BONE METASTASIS; BONE NECROSIS; BONE PAIN; BONE TURNOVER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER OF UNKNOWN PRIMARY SITE; CENTRAL NERVOUS SYSTEM METASTASIS; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CREATININE URINE LEVEL; DEPRESSION; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FRACTURE; GASTRITIS; HUMAN; HYPOCALCEMIA; INSOMNIA; KIDNEY FUNCTION; LARGE INTESTINE CANCER; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; MULTIPLE MYELOMA; MUSCULOSKELETAL PAIN; NAUSEA; OPEN STUDY; ORTHOPEDIC SURGERY; PARESTHESIA; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SPINAL CORD COMPRESSION; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; THYROID CANCER; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; URINE LEVEL; UTERINE CERVIX CANCER; UTERUS CANCER; VERTEBRA FRACTURE;

AGED; ANTIBODIES, MONOCLONAL; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BONE RESORPTION; BREAST NEOPLASMS; COLLAGEN TYPE I; DIPHOSPHONATES; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PEPTIDES; PROSTATIC NEOPLASMS; RANK LIGAND;

EID: 63749094012     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.19.2146     Document Type: Article

References (23)

1. Coleman RE: Skeletal complications of malignancy. Cancer 80:1588-1594, 1997
2. Coleman RE: Metastatic bone disease: Clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165-176, 2001
3. Berenson JR, Hillner BE, Kyle RA, et al: American Society of Clinical Oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma. J Clin Oncol 20:3719-3736, 2002
4. Body JJ, Mancini I: Bisphosphonates for cancer patients: Why, how, and when? Support Care Cancer 10:399-407, 2002
5. Hillner BE, Ingle JN, Chlebowski RT, et al: American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:4042-4057, 2003
6. Coleman RE, Major P, Lipton A, et al: Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23:4925-4935, 2005
7. Brown JE, Cook RJ, Major P, et al: Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97:59-69, 2005
8. Brown JE, Thomson CS, Ellis SP, et al: Bone resorption predicts for skeletal complications in met- astatic bone disease. Br J Cancer 89:2031-2037, 2003
9. Costa L, Demers LM, Gouveia-Oliveira A, et al: Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol 20: 850-856, 2002
10. Rajpar S, Laplanche A, Tournay E, et al: Prognostic value of urinary N-telopeptide (uNTX) in patients (pts) with castration-resistant prostate cancer (CRPC) and bone metastases. J Clin Oncol 26:283s, 2008 (suppl; abstr 5138)
11. Demers LM, Costa L, Lipton A: Biochemical markers and skeletal metastases. Cancer 88:2919-2926, 2000
12. Lacey DL, Timms E, Tan HL, et al: Osteo- protegerin ligand is a cytokine that regulates oste- oclast differentiation and activation. Cell 93:165-176, 1998
13. Roodman GD: Biology of osteoclast activation in cancer. J Clin Oncol 19:3562-3571, 2001
14. Fizazi K, Yang J, Peleg S, et al: Prostate cancer cells-osteoblast interaction shits expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clin Cancer Res 9:2587-2597, 2003
15. Yang J, Fizazi K, Peleg S, et al: Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway. Cancer Res 61:5652-5659, 2001
16. Roodman GD: Mechanisms of bone metastasis. N Engl J Med 350:1655-1664, 2004
17. Bekker PJ, Holloway DL, Rasmussen AS, et al: A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 19: 1059-1066, 2004
18. Body JJ, Facon T, Coleman RE, et al: A study of the biological receptor activator of nuclear factor- kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 12:1221-1228, 2006
19. McClung MR, Lewiecki EM, Cohen SB, et al: Denosumab in postmenopausal women with low
20. bone mineral density. N Engl J Med 354:821-831, 2006
21. Lipton A, Steger GG, Figueroa J, et al: Randomized active-controlled phase II study of deno- sumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 25: 4431-4437, 2007
22. Fizazi K: The role of Src in prostate cancer. Ann Oncol 18:1765-1773, 2007
23. Fizazi K, Beuzeboc P, Lumbroso J, et al: A prospective phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol (in press)